HRTX Q3 2020 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$153M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M-53.2% YoY

Gross Profit

$13M64.1% margin

Operating Income

-$58M-292.4% margin

Net Income

-$58M-291.7% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

-11.9%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$43M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$390M

Total Liabilities

$113M

Stockholders' Equity

$277M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$43M	-53.2%
Gross Profit	$13M	$25M	-49.7%
Operating Income	-$58M	-$35M	-67.5%
Net Income	-$58M	-$34M	-73.3%

Revenue Segments

C I N V A N T I

$20M99%

S U S T O L

$200,0001%